Calcium Pyrophosphate Disease - Acute Arthritis Management

Key Points

• Acute CPP crystal arthritis can be clinically indistinguishable from septic arthritis.
• Arthrocentesis should include crystal analysis and culture when infection is possible.
• CPP crystals are classically rhomboid and weakly positively birefringent.
• Joint aspiration plus intra-articular steroid is highly effective for accessible monoarthritis after excluding infection.
• NSAID, colchicine, or short systemic steroid therapy is selected according to comorbidity.
• Chondrocalcinosis supports CPPD but is neither required nor sufficient for the diagnosis of an acute attack.
• Consider metabolic associations in younger or unusually extensive CPPD.
• There is no proven crystal-depleting treatment equivalent to urate-lowering therapy.

Algorithm

1. Assess the acutely inflamed joint and systemic sepsis risk.
2. Perform arthrocentesis for significant new monoarthritis or when infection cannot be confidently excluded.
3. Send synovial cell count, Gram stain/culture, and polarized crystal analysis.
4. Obtain radiographs or ultrasound when useful for chondrocalcinosis and alternate pathology.
5. Treat accessible monoarthritis with aspiration and intra-articular steroid once infection is excluded.
6. Use NSAID, colchicine, or short systemic steroid for broader disease based on renal/GI/cardiovascular risks.
7. For recurrent disease, consider low-dose colchicine prophylaxis and rheumatology follow-up.
8. Evaluate iron, calcium/PTH, magnesium and thyroid status in younger or atypical presentations.

Clinical Synopsis & Reasoning

CPPD encompasses asymptomatic chondrocalcinosis, acute CPP crystal arthritis, osteoarthritis with CPPD, and chronic inflammatory CPP crystal arthritis. Acute attacks commonly involve the knee, wrist, shoulder, ankle, or elbow and can cause striking warmth, swelling, fever, leukocytosis, and elevated inflammatory markers. Because septic arthritis can look identical and may coexist with crystals, a first severe monoarthritis or an immunocompromised patient should generally undergo arthrocentesis rather than being diagnosed from radiographic chondrocalcinosis alone.

Synovial fluid typically shows positively birefringent rhomboid calcium pyrophosphate crystals under compensated polarized light microscopy, but crystal identification can be difficult and a negative specimen does not completely exclude CPPD. Send cell count, Gram stain, and culture when infection is a concern. Radiographs may show chondrocalcinosis in fibrocartilage or hyaline cartilage, but absence does not exclude disease. In a younger patient or unusually extensive disease, evaluate associated metabolic disorders including hemochromatosis, hyperparathyroidism, hypomagnesemia, and hypothyroidism. Acute illness, surgery, and trauma can precipitate attacks.

Treatment Strategy & Disposition

For one or two accessible joints, aspiration followed by intra-articular glucocorticoid is often highly effective after infection has been reasonably excluded. NSAIDs are useful when kidney, GI, cardiovascular, and anticoagulation risks permit. Low-dose colchicine can shorten attacks when started early and is also used as prophylaxis for recurrent episodes, but renal function and CYP3A4/P-glycoprotein interactions must be considered. A short course of oral or parenteral glucocorticoid is appropriate when NSAIDs and colchicine are unsuitable or polyarticular disease makes injections impractical.

There is no established therapy that removes CPP crystal deposits analogous to urate lowering in gout. Treat associated metabolic disorders for their own indications, although doing so may not reverse existing chondrocalcinosis. Recurrent or chronic CPP inflammatory arthritis can require low-dose colchicine, NSAIDs with gastroprotection, low-dose glucocorticoids, or rheumatology-directed DMARD/biologic strategies in selected refractory disease. Avoid unnecessary antibiotics once infection is excluded, but never allow crystal identification alone to override a positive culture or convincing septic phenotype.

Epidemiology / Risk Factors

• CPPD prevalence rises sharply with age and is common in older adults.
• The knee and wrist are frequent sites, but almost any peripheral joint can be affected.
• Hemochromatosis, hyperparathyroidism, hypomagnesemia, and some inherited disorders increase risk.
• Acute attacks may follow surgery, trauma, or severe medical illness.

Investigations

Associated Conditions

Pharmacology

Prognosis / Complications

• Acute attacks usually resolve over days to weeks with appropriate anti-inflammatory treatment.
• Recurrent attacks and chronic inflammatory arthritis can substantially impair function.
• Underlying osteoarthritis may remain symptomatic between inflammatory episodes.
• Long-term prognosis depends more on joint damage and comorbidity than on acute crystal inflammation itself.

Patient Education / Counseling

• Explain that CPPD is a crystal arthritis like gout but involves calcium pyrophosphate, not uric acid.
• Seek urgent reassessment for persistent fever, bacteremia risk, worsening pain despite treatment, or inability to bear weight because infection may still be present.
• Review kidney, GI, heart, and anticoagulation history before self-treating with NSAIDs.
• If colchicine is prescribed, check for major antibiotic/antifungal interactions before taking it.
• For recurrent disease, keep a written plan identifying which anti-inflammatory agent is safest.

Notes

CPPD management should not be copied from gout. The acute inflammatory treatments overlap, but there is no serum-urate target and no established drug that dissolves calcium pyrophosphate crystals. This distinction prevents unnecessary allopurinol or febuxostat prescribing.

The other major pitfall is premature diagnostic closure after crystals are seen. Septic arthritis remains possible, particularly in older, immunosuppressed, bacteremic, prosthetic-joint, or recently operated patients. Culture and clinical trajectory determine whether antibiotics and surgical management are still required.

References

1. EULAR Recommendations for Calcium Pyrophosphate Deposition, Part II: Management — Link